Jump to content
Wikipedia The Free Encyclopedia

Tetrabamate

From Wikipedia, the free encyclopedia
Combination drug
Pharmaceutical compound
Tetrabamate
Combination of
Febarbamate Carbamate, barbiturate
Difebarbamate Carbamate, barbiturate
Phenobarbital Barbiturate
Identifiers
CAS Number
ChemSpider
ChEMBL

Tetrabamate (Atrium, G Tril, Sevrium) is a combination drug formulation of febarbamate, difebarbamate, and phenobarbital which was marketed in France and Spain and was used to treat anxiety and alcohol withdrawal-associated muscle tremors, agitation, and depression.[1] [2] [3] [4] It was largely, but not completely discontinued on April 4, 1997, after over 30 years of use due to reports of hepatitis and acute liver failure.[3] [4] [5] [6] The decision to restrict the use of the drug had been long-awaited.[clarification needed ][6]

References

[edit ]
  1. ^ Index nominum 2000: international drug directory. Taylor & Francis US. 2000. pp. 333 & 427. ISBN 978-3-88763-075-1 . Retrieved 26 November 2011.
  2. ^ Chitturi S, Farrell GC (19 October 2011). "Drug-Induced Liver Disease". In Schiff ER, Maddrey WC, Sorrell MF (eds.). Schiff's Diseases of the Liver. John Wiley and Sons. pp. 703–783. doi:10.1002/9781119950509.ch27. ISBN 978-1-119-95048-6 . Retrieved 26 November 2011.
  3. ^ a b Binder D, Jost R, Flury R, Salomon F (May 1995). "[Acute liver failure following tetrabamate]". Schweizerische Medizinische Wochenschrift (in German). 125 (19): 965–969. PMID 7761807.
  4. ^ a b Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments. United Nations Publications. 2003. p. 259. ISBN 978-92-1-130230-1 . Retrieved 26 November 2011.[permanent dead link ]
  5. ^ Horsmans Y, Lannes D, Pessayre D, Larrey D (December 1994). "Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate". Journal of Hepatology. 21 (6): 1075–1079. doi:10.1016/s0168-8278(05)80620-8. PMID 7699230.
  6. ^ a b "Severe hepatitis due to Atrium". Prescrire International. 10 (55): 150. October 2001. PMID 11824432.
Treatment of drug dependence (N07B)
Nicotine dependence
Alcohol dependence
Opioid dependence
Benzodiazepine dependence
5-HT1AR Tooltip 5-HT1A receptor agonists
GABAAR Tooltip GABAA receptor PAMs Tooltip positive allosteric modulators
Hypnotics
Gabapentinoids
(α2δ VDCC blockers)
Antidepressants
Antipsychotics
Sympatholytics
(Antiadrenergics)
Others
Peripherally acting
(primarily antinicotinic,
NMJ block)
Non-depolarizing
Curare alkaloids
4° ammonium agents
Depolarizing
ACh release inhibitors
Centrally acting
Carbamic acid esters
Benzodiazepines
Nonbenzodiazepines
Thienodiazepines
Quinazolines
Anticholinergics
(Antimuscarinics)
Other
Directly acting
GABAA
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Imidazoles
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Quinazolinones
Others
GABAB
H1
Antihistamines
Antidepressants
Antipsychotics
α2-Adrenergic
5-HT2A
Antidepressants
Antipsychotics
Others
Melatonin
Orexin
α2δ VDCC
Others
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Flavonoids
Imidazoles
Kava constituents
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Pyrazolopyridines
Quinazolinones
Volatiles/gases
Others/unsorted

AltStyle によって変換されたページ (->オリジナル) /